References
- Alex R, Bodmeier R. Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment. Journal of Microencapsulation 1990; 3: 347–355
- Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human erythropoietin (rhEPO) loaded poly(lactideco-glycolide) microspheres: Influence of the encapsulation technique and polymer purity on microsphere characteristics. European Journal of Pharmaceutics and Biopharmaceutics 1998; 45: 295–305
- Chen JL, Yeh MK, Chiang CH. The mechanism of surface-idented protein-loaded PLGA microparticle formulation: The effect of salt (NaCl) on the solidification process. Journal of Microencapsulation 2004; 21: 877–888
- Chuang VTG, Ulrich KH, Otagiri1 M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharmaceutical Research 2002; 19: 569–577
- Coombes AGA, Yeh MK, Eavelle EC, Davis SS. The control of protein release from poly(Dl lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. Journal of Controlled Release 1998; 52: 311–320
- Crotts G, Park TG. Stability and release of bovine serum albumin encapsulated within poly(Dl-lactide-co-glycolide) microparticles. Journal of Controlled Release 1997; 44: 123–134
- Dube S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. Journal of Biological Chemistry 1998; 263: 17516–17521
- Eavelle EC, Yeh MK, Coombes AGA, Davis SS. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 1999; 17: 512–529
- Eguene JM. Protein formulation and delivery. New York 2000; 90–91
- Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharmaceutical Research 2003; 20: 1903–1907
- Kendall RG. Erythropoietin. Clinical Laboratory Haematology 2001; 23: 71–80
- Kim HK, Park TG. Microencapsulation of human growth hormone within biodegradable polyester microspheres: Protein aggregation, stability and incomplete release mechanism. Biotechnology and Bioengineering 1999; 65: 659–667
- Maa Y, Hsu C. Effect of primary emulsions on microsphere size and protein loading in the double emulsion process. Journal of Microencapsulation 1997; 14: 225–241
- Morlock M, Kissel T, Li YX, Koll H, Winter G. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: Protein stabilization and in-vitro release properties. Journal of Controlled Release 1998; 56: 105–115
- Nihant N, Schugens C, Grandfiles C, Jerome R, Teyssie P. Polylactide microparticles prepared by double emulsion/evaporaion technique. I. Effect of primary emulsion stability. Pharmaceutical Research 1994; 11: 1479–1484
- Perez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. Journal of Pharmaceutics and Pharmacology 2002; 54: 301–313
- Pistel K, Bittner B, Koll H, Winter G, Kissel T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: Influence of encapsulation technique and polymer composition on particle characteristics. Journal of Controlled Release 1999; 59: 309–325
- Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Natural Biotechnology 1998; 16: 153–157
- Siren AL, Ehrenreich H. Erythropoietin—a novel concept for neuroprotection. European Archives of Psychiatry Clinics in Neuroscience 2001; 251: 179–184
- Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626–3634
- Veronese FM. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 2001; 22: 405–417
- Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research 2000; 17: 1159–1167
- Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Renal Failure 2001; 23: 563–571
- Yeh MK. The stability of insulin in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Journal of Microencapsulation 2000; 17: 743–756
- Yeh MK, Chiang CH. Inactived vibrio cholerae whole-cell vaccine-loaded bidegradable microparticles: In vitro release and oral vaccination. Journal of Microencapsulation 2003; 21: 91–106
- Yeh MK, Chen JL, Chiang CH. Vibrio cholerae-loaded poly(DL lactide co-glycolide) microparticles. Journal of Microencapsulation 2002; 19: 203–212
- Yeh MK, Chen JL, Chiang CH. In vivo and in vitro characteristics for insulin-loaded PLA microparticles prepared by w/o/w solvent evaporation method with electrolytes in the continuous phase. Journal of Microencapsulation 2004; 21: 719–728
- Yeh MK, Davis SS, Coombes AGA. Improving delivery of proteins from microparticles using blends of poly(Dl lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Pharmaceutical Research 1996; 13: 1693–1698
- Yeh MK, Coombes AGA, Jenkins PG, Davis SS. A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery. Journal of Controlled Release 1995; 33: 437–445